KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Short term Debt (2016 - 2025)

Pacira BioSciences (PCRX) has 15 years of Short term Debt data on record, last reported at $202.4 million in Q2 2025.

  • For Q2 2025, Short term Debt changed N/A year-over-year to $202.4 million; the TTM value through Jun 2025 reached $202.4 million, changed N/A, while the annual FY2024 figure was $201.8 million, 2235.1% up from the prior year.
  • Short term Debt reached $202.4 million in Q2 2025 per PCRX's latest filing, roughly flat from $202.1 million in the prior quarter.
  • Across five years, Short term Debt topped out at $202.4 million in Q2 2025 and bottomed at $8.6 million in Q4 2023.
  • Average Short term Debt over 5 years is $95.6 million, with a median of $33.9 million recorded in 2022.
  • Peak YoY movement for Short term Debt: tumbled 83.81% in 2021, then soared 2238.69% in 2025.
  • A 5-year view of Short term Debt shows it stood at $24.2 million in 2021, then surged by 39.77% to $33.9 million in 2022, then plummeted by 74.49% to $8.6 million in 2023, then soared by 2235.1% to $201.8 million in 2024, then grew by 0.31% to $202.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $202.4 million in Q2 2025, $202.1 million in Q1 2025, and $201.8 million in Q4 2024.